Neoadjuvant therapy in melanoma: The fast track to critical new answers

摘要

H&O What are the potential advantages of neoadjuvant therapy in melanoma?:AT Outcomes are poor for patients with melanoma who are candidates for neoadjuvant therapy; that is, those who have locally or regionally advanced melanoma that is surgically operable. The 5-year tumor recurrence rate for these patients has been reported at approximately 68% to 89% after prior surgical management. The use of newer immunotherapies, targeted agents, and combinations has the potential to make a major impact in the management of these patients.